Alexander Hardy
Alexander Hardy appointed as BioMarin's CEO, bringing 30+ years of experience and a track record of driving commercial growth, including a 24% revenue increase at Genentech.
Hardy plans to leverage his global product strategy and drug launch expertise to focus BioMarin's R&D on high-potential assets, aiming to boost revenue and margins.
Despite being critiqued for strategy and arrogance, Hardy's former colleagues at Genentech and Roche rate him highly for integrity, CEO fitness, and communication skills.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.